ACTRN12613001296729已完成2 期
A Phase II, Multi-Centre, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection.
Biotron Limited0 个研究点目标入组 60 人开始时间: 2013年11月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1.Males or females aged 18 to 65 years.
- •2.Chronic hepatitis C infection (HCV RNA in the blood at least 6 months from initial detection).
- •3.Positive anti-HCV antibody test.
- •4. HCV genotype 1 or 3
- •5. HCV RNA of >/= 10^5 IU/mL within 60 days of Entry.
- •6.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) less than or equal to 10 times ULN (upper level of normal) within 60 days of Day 1.
- •7.Females of reproductive potential must have a negative serum or urine pregnancy test within 24 hours of Day 1.
- •8.Not to participate in a conception process. If participating in sexual activity that could lead to pregnancy, the participant must agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 6 months after stopping study treatment.
- •9.Participants who are not of reproductive potential are eligible without requiring the use of contraceptives.
- •10.Provide written informed consent to participate in the study and be willing to comply with the study procedures.
- •11.Naive to therapy for HCV, including any IFN or RBV.
排除标准
- •1.Received an investigational drug, immunomodulator, systemic cytotoxic chemotherapy, or other investigational therapy within 30 days prior to Day 1.
- •2.Positive results for Hepatitis B and/or HIV antibody at Screening.
- •3.History or presence of other evidence of a medical condition associated with chronic liver disease.
- •4.Bridging cirrhosis or cirrhosis confirmed on a liver biopsy, or ultrasound and fibroscan, obtained within the past 36 months as judged by a local pathologist.
- •5.History or signs of decompensated liver disease.
- •6.History or other evidence of clinically significant renal disease.
- •7.Pregnancy or breast feeding, male partners of pregnant females.
- •8.Abnormal haematological and biochemical parameters within 60 days of Entry:
- •a.Absolute neutrophil count <1000/mm^3
- •b.Haemoglobin <12 g/dL in females or 13 g/dL in males
- •c.Platelet count <150,000/mm^3
- •d.International normalized ratio (INR) >1.5
- •e.Total bilirubin > 1.5 times the normal reference range
- •f.Creatinine > 1.5 mg/dL
- •Estimated creatinine clearance < 60 mL/minute at Screening. Value will be calculated using the Cockcroft-Gault formula.
- •9.Screening ECG QTcB value > 450 ms.
- •10.The consumption / administration of excluded concomitant medication (prescribed, over-the-counter or complementary) at the time of the Screening visit.
- •11.Active drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements.
- •12. A positive result on urine screen for drugs of abuse at Screening or Day 1.
- •13.History of severe psychiatric disease, or depression which in the opinion of the Investigator could be exacerbated by IFN therapy. Uncontrolled or active depression or other psychiatric disorder such as untreated Grade 3 or higher psychiatric disorder, Grade 3 or higher disorder not amenable to medical intervention, or any hospitalization within the past 52 weeks that in the opinion of the site Investigator might preclude tolerability of study requirements.
- •14.Any prior suicide attempt.
- •15.History of immunologically mediated disease that may be exacerbated by interferon use.
- •16.History or other evidence of chronic pulmonary disease associated with functional limitation.
- •17.History of documented or presumed coronary artery disease or cardiovascular disease, clinically significant arrhythmia.
- •18.History of a severe seizure disorder or current anticonvulsant use.
- •19.History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.
- •20.Evidence of an active or suspected cancer or a history of malignancy within 2 years of the study.
- •21.History of having received any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- •22.Active thyroid disease.
- •23.Any patient with a baseline increased risk for anaemia or for whom anaemia would be medically problematic.
- •24.History or other evidence of severe retinopathy.
- •25.Serious illness requiring systemic treatment and/or hospitalization until the participant either completes therapy or is clinically stable on therapy, in the opinion of the site Investigator, or at least 7 days prior to study entry.
- •26.Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation.
- •27.Unable to
研究者
相似试验
已完成
2 期
A clinical trial to study the efficacy & Safety of IV of TK-112690 a new experimental drug to a placebo as a mucositis preventive in subjects with squamous cell cancer of Head & Neck scheduled to receive Methotrexate as chemotherapyCTRI/2019/05/018909TOSK INC22
进行中（未招募）
2 期
A Phase II Study of NTPI in Patients with Behavioral and Psychological Symptoms Associated with Alzheimer's Disease.JPRN-jRCT2071220042Toyama Ikuo90
进行中（未招募）
1 期
A multi-center clinical study with LJPC-401 for the treatment of iron overload in adult patients with hereditary hemochromatosisHereditary HemochromatosisMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003598-33-GBa Jolla Pharmaceutical Company76
撤回
2 期
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients1. Sepsis2. A life-threateningmedical emergency caused by an infection in the blood stream that can affect different organs10019815NL-OMON53483Enlivex Therapeutics R&D Ltd;7
进行中（未招募）
1 期
Phase 2 study to evaluate efficacy and safety of Allocetra-OTS in patients with sepsisMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsSepsisEUCTR2021-003273-66-NLEnlivex Therapeutics R&D Ltd.160